Abstract
Background Diffuse myocardial fibrosis is present in several cardiomyopathies. Contrast enhanced cardiac MR with T1 mapping enables quantification of diffuse fibrosis. T1 mapping is technically demanding since technical, physiological, and biochemical factors can interfere with T1 measurements. Contrast material dose, relaxivity, biodistribution, clearance, interaction with plasma proteins, and interference with co-medication must be taken into consideration. Gadobenate dimeglumine (GdBOPTA) has some weak protein binding capacities and higher molar relaxivity in plasma/blood resulting in shorter T1 times as compared to other extracellular gadolinium based contrast agents. To date it has not been assessed whether co-medication with other protein binding drugs alter myocardial T1 time. Therefore the aim of this study was to evaluate the interference of a typical protein binding drug (Ibuprofen) with GdBOPTA with respect to T1 times in vitro and in vivo. Methods
Highlights
Diffuse myocardial fibrosis is present in several cardiomyopathies
Gadobenate dimeglumine (GdBOPTA) has some weak protein binding capacities and higher molar relaxivity in plasma/blood resulting in shorter T1 times as compared to other extracellular gadolinium based contrast agents
T1 values for myocardium and blood pool were determined for various time points after administration of 0.15 mmol/kg gadobenate dimeglumine using a modified look-locker inversion-recovery sequence before and after administration of Ibuprofen over 24 hours
Summary
Diffuse myocardial fibrosis is present in several cardiomyopathies. Contrast enhanced cardiac MR with T1 mapping enables quantification of diffuse fibrosis. Relaxivity, biodistribution, clearance, interaction with plasma proteins, and interference with co-medication must be taken into consideration. Gadobenate dimeglumine (GdBOPTA) has some weak protein binding capacities and higher molar relaxivity in plasma/blood resulting in shorter T1 times as compared to other extracellular gadolinium based contrast agents. To date it has not been assessed whether co-medication with other protein binding drugs alter myocardial T1 time. The aim of this study was to evaluate the interference of a typical protein binding drug (Ibuprofen) with GdBOPTA with respect to T1 times in vitro and in vivo
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
